Research & Publications > Clinical
Research > Cardiovascular
Disease Prevention Center > Cardiovascular
Disease Prevention Center
(Continued)
A 6-Week Randomized, Double-Blind, Multicenter Trial to Evaluate the Safety and Efficacy of ZD4522 (5, 10, 20, 40 and 80 mg) and Atorvastatin (10, 20, 40 and 80 mg) Across their Respective Dose Ranges in the Treatment of Subjects with Hypercholesterolemia
Sponsor: AstraZeneca/Covance, Inc.
Dates: 10/99 - 7/01
Principal Investigator: John Morgan, MD
An Open-Label, Multinational, Multicenter, Extension Trial to Assess the Long-Term Safety and Efficacy of ZD4522 in Subjects in the ZD4522 Clinical Trial Program
Study: ZD4522IL/0034
Sponsor: AstraZeneca/Covance, Inc.
Dates: 9/99 - 9/00
Principal Investigator: John Morgan, MD
An Extended Safety, Efficacy and Tolerability Study of Lovastatin XL in Patients with Hyperlipidemia
Protocol: 146-011
Sponsor: Aura Laboratories, Inc.
Dates: 1/00 - 12/00
Principal Investigator: John Morgan, MD
A Multicenter, Randomized, Double-Blind, Parallel-Group, Clinical Evaluation of Oral G1262570 Sodium Tablets (2.5 mg, 5 mg and 7.5 mg G1262570) in Combination with Metformin for 26 Weeks Duration in Subjects with Type 2 Diabetes Mellitus who are Inadequately Controlled on a Maximum Dose of Metformin
Protocol: PPA3002
Sponsor: Glaxo Wellcome, Inc.
Dates: 10/99 - 9/00
Principal Investigator: John Morgan, MD
Phase II, Dose-Response Study of Oral NO-18866 in Subjects with Marked Hypertriglyceridemia
Protocol: 1886-99-004
Sponsor: Tap Holdings, Inc.
Dates: 4/00 - 4/01
Principal Investigator: John Morgan, MD
A Randomized, Double-Blind, Placebo-Controlled Trial of Once Per Day Versus Split Dosing of GT102-279 in Patients with Primary Hypercholesterolemia
Protocol: GTC-55-202
Sponsor: Geltex Pharmaceuticals
Dates: 4/00 - 4/01
Principal Investigator: John Morgan, MD
Effects of walnuts consumption as part of a low-fat, low-cholesterol diet on serum cardiovascular risk factors
Morgan JM, Walker K, Horton K, Reese D, Capuzzi D.
Inter J Vit and Nut Research (in press) 2002.
Effectiveness of colesevelam hydrochloride in decreasing LDL cholesterol in patients with primary hypercholesterolemia
Insull W, Toth P, Mullican W, Hunninghake D, Burke S, Donovan J, Davidson M. (Contributing Research Center – Morgan JM).
A 24 week randomized controlled trial. Mayo Clin Proc. Vol 76. Oct 2001.
< Back
|
|
